Aptinyx Inc

Aptinyx — Investor Presentation (March 2019)

16 slides from Aptinyx's investor presentation, Mar 13, 2019

  1. Slide 1: Forward-looking statements

    Forward-looking statements This presentation has been prepared by Aptinyx Inc. (“we,” ”us,” “our,” “Aptinyx,” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any sec

  2. Slide 2: Clinical-stage biopharmaceutical company developing NMDA receptor-modulating therapies

    POSITIVE HUMAN DATA in Phase 1 and Phase 2a clinical studies Clinical-stage biopharmaceutical company developing transformative NMDA receptor-modulating therapies 3 TARGETING RELEVANT DISEASE AREAS with significant unmet need & commercial opportunity ROBUST IP afforded through internal innovation an

  3. Slide 3: Significant unmet need in chronic pain, PTSD and Parkinson's cognitive impairment

    4 Affects up to 100mm people in the U.S. Current therapies have limited efficacy and substantial side effects Market leading therapies have significant drawbacks, yet have garnered >$5bn in annual revenues each Significant abuse liability Chronic Pain ~8.5mm people suffering from PTSD in the U.S. Ca

  4. Slide 4: Modulation: a differentiated approach to targeting the NMDA receptor

    Modulation: A differentiated approach to targeting the NMDA receptor VS. 5 NMDAr-targeted drugs discovered to date (largely inhibitors, e.g., PCP, ketamine) have significant limitations

  5. Slide 5: Prolific output from Aptinyx NMDAr modulator discovery platform

    Prolific output from Aptinyx small-molecule NMDAr modulator discovery platform Dozens of novel chemical scaffolds Novel, distinct, newly characterized binding domain High oral bioavailability and stability Diverse potency, activity, subtype selectivity, and pharmacology/biology profiles Composition

  6. Slide 6: Multiple clinical-stage development programs across various CNS indications

    Multiple clinical-stage development programs across various CNS indications 7 NYX-2925 NYX-783 NYX-458 AGN-241751 Painful Diabetic Peripheral Neuropathy Fibromyalgia Post-Traumatic Stress Disorder Parkinson’s Disease Cognitive Impairment Indication Est. U.S. Prevalence Next Milestone Phase 1 Phase 2

  7. Slide 7: NYX-2925 in Phase 2 clinical development for treatment of chronic pain

    Increases non-REM sleep without impacting REM sleep Shows positive effects on pain processing and pain in patients with fibromyalgia and painful DPN NYX-2925 in Phase 2 clinical development for treatment of chronic pain Strong mechanistic rationale Safety and activity observed to date suggest NYX-29

  8. Slide 8: Exploratory biomarker and efficacy study of NYX-2925 in fibromyalgia

    Exploratory biomarker and efficacy study of NYX-2925 in patients with fibromyalgia Primary endpoints known to be correlated with pain improvement and are a direct measure of drug effect 9 Aptinyx & U of M used fMRI to evaluate effects of NYX-2925 Building on prior work of University of Michigan Glut

  9. Slide 9: NYX-2925 effects on pain processing in fibromyalgia patients

    Significantly lower pain-evoked increases in posterior insula Glx Reduced connectivity between insular cortex and default mode network Significant reductions of Glx levels in dorsal anterior cingulate cortex Corresponding trends of improvement on clinical pain scores, cognitive impairment, fibromyal

  10. Slide 10: Phase 2 study of NYX-2925 in painful diabetic peripheral neuropathy

    Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN) 11 Placebo q.d. (n = 72) Inclusion/ exclusion eligibility Analgesic washout* Daily Pain Score NYX-2925 10mg q.d. (n = 77) NYX-2925 50mg q.d. (n = 77) NYX-2925 200mg q.d. (n = 74) *Patients were allowed to maintai

  11. Slide 11: NYX-2925 showed significant effects in advanced DPN sub-population

    NYX-2925 showed significant effects across primary and secondary endpoints in a highly relevant patient sub-population 12 Change in average daily pain vs. placebo (primary efficacy endpoint) Total efficacy population (N=300) Advanced DPN population (N=127)* *Post-hoc analysis of advanced DPN populat

  12. Slide 12: Key findings provide scientific foundation for further development of NYX-2925

    Key findings provide scientific foundation for further development of NYX-2925 NYX-2925 showed excellent safety profile – AEs comparable to placebo and no SAEs Patients with advanced DPN showed the greatest treatment benefit Mechanism of NYX-2925 addresses the increasing central manifestation of pai

  13. Slide 13: NYX-783 in Phase 2 clinical development for treatment of PTSD

    Favorable safety, tolerability, CNS exposure, and PK in Phase 1 2 approved SSRIs – approved 10+ years ago Limited efficacy – only targeting symptoms Burdensome side effects with current therapies NYX-783 in Phase 2 clinical development for treatment of PTSD Strong preclinical & early clinical eviden

  14. Slide 14: First-in-patient Phase 2 study of NYX-783 for PTSD

    First-in-patient Phase 2 study of NYX-783 for the treatment of post-traumatic stress disorder 15 Data from this first-in-patient study expected 1H 2020 Screening Placebo non-responders Placebo non-responder criteria: CAPS-5 reduction from baseline <35% CAPS-5 score @ re-randomization >26 Stage 1 (4

  15. Slide 15: NYX-458 in clinical development for Parkinson's disease cognitive impairment

    NYX-458 in clinical development for treatment of Parkinson’s disease cognitive impairment Strong preclinical evidence in cognition and Parkinson’s disease models Clear mechanistic rationale NYX-458 enhances synaptic plasticity and LTP through NMDAr modulation NMDAr dysregulation and dysfunction caus

  16. Slide 16: NYX-458 in clinical development for Parkinson's disease cognitive impairment

    NYX-458 in clinical development for treatment of Parkinson’s disease cognitive impairment Clear mechanistic rationale Substantial opportunity © NYX-458 enhances synaptic plasticity and LTP © Significant unmet need through NMDAr modulation © Concentrated patient and prescriber base © NMDAr dysregulat

Aptinyx — Investor Presentation (March 2019) on 6ix